MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $944.94 million. The enterprise value is $911.04 million.
| Market Cap | 944.94M |
| Enterprise Value | 911.04M |
Important Dates
The next confirmed earnings date is Tuesday, April 30, 2024, after market close.
| Earnings Date | Apr 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 146.96 million shares outstanding. The number of shares has increased by 29.27% in one year.
| Shares Outstanding | 146.96M |
| Shares Change (YoY) | +29.27% |
| Shares Change (QoQ) | +22.32% |
| Owned by Insiders (%) | 3.76% |
| Owned by Institutions (%) | 61.59% |
| Float | 116.20M |
Valuation Ratios
The trailing PE ratio is 17.38 and the forward PE ratio is 20.01. MiMedx Group's PEG ratio is 2.97.
| PE Ratio | 17.38 |
| Forward PE | 20.01 |
| PS Ratio | 2.94 |
| Forward PS | 2.59 |
| PB Ratio | 6.62 |
| P/FCF Ratio | 38.12 |
| PEG Ratio | 2.97 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.97, with an EV/FCF ratio of 36.75.
| EV / Earnings | 15.65 |
| EV / Sales | 2.83 |
| EV / EBITDA | 27.97 |
| EV / EBIT | 32.68 |
| EV / FCF | 36.75 |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.34.
| Current Ratio | 3.57 |
| Quick Ratio | 2.95 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 1.48 |
| Debt / FCF | 1.94 |
| Interest Coverage | 4.32 |
Financial Efficiency
Return on equity (ROE) is 205.30% and return on invested capital (ROIC) is 52.83%.
| Return on Equity (ROE) | 205.30% |
| Return on Assets (ROA) | 30.10% |
| Return on Capital (ROIC) | 52.83% |
| Revenue Per Employee | $359,192 |
| Profits Per Employee | $65,059 |
| Employee Count | 895 |
| Asset Turnover | 1.66 |
| Inventory Turnover | 3.19 |
Taxes
| Income Tax | -36.81M |
| Effective Tax Rate | -171.81% |
Stock Price Statistics
The stock price has increased by +70.56% in the last 52 weeks. The beta is 1.38, so MiMedx Group's price volatility has been higher than the market average.
| Beta (1Y) | 1.38 |
| 52-Week Price Change | +70.56% |
| 50-Day Moving Average | 7.55 |
| 200-Day Moving Average | 7.54 |
| Relative Strength Index (RSI) | 36.25 |
| Average Volume (30 Days) | 799,266 |
Short Selling Information
The latest short interest is 5.18 million, so 3.52% of the outstanding shares have been sold short.
| Short Interest | 5.18M |
| Short Previous Month | 5.52M |
| Short % of Shares Out | 3.52% |
| Short % of Float | 4.45% |
| Short Ratio (days to cover) | 5.18 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $321.48 million and earned $58.23 million in profits. Earnings per share was $0.37.
| Revenue | 321.48M |
| Gross Profit | 266.84M |
| Operating Income | 37.09M |
| Pretax Income | 21.42M |
| Net Income | 58.23M |
| EBITDA | 32.57M |
| EBIT | 27.88M |
| Earnings Per Share (EPS) | $0.37 |
Balance Sheet
The company has $82.00 million in cash and $48.10 million in debt, giving a net cash position of $33.90 million or $0.23 per share.
| Cash & Cash Equivalents | 82.00M |
| Total Debt | 48.10M |
| Net Cash | 33.90M |
| Net Cash Per Share | $0.23 |
| Equity / Book Value | 142.72M |
| Book Value Per Share | 0.97 |
| Working Capital | 118.25M |
Cash Flow
In the last 12 months, operating cash flow was $26.78 million and capital expenditures -$1.99 million, giving a free cash flow of $24.79 million.
| Operating Cash Flow | 26.78M |
| Capital Expenditures | -1.99M |
| Free Cash Flow | 24.79M |
| FCF Per Share | $0.21 |
Margins
Gross margin is 83.01%, with operating and profit margins of 11.54% and 18.11%.
| Gross Margin | 83.01% |
| Operating Margin | 11.54% |
| Pretax Margin | 6.66% |
| Profit Margin | 18.11% |
| EBITDA Margin | 10.13% |
| EBIT Margin | 8.67% |
| FCF Margin | 7.71% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.27% |
| Shareholder Yield | -29.27% |
| Earnings Yield | 6.16% |
| FCF Yield | 2.62% |
Analyst Forecast
The average price target for MiMedx Group is $12.25, which is 90.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.25 |
| Price Target Difference | 90.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 11.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 2, 2008. It was a reverse split with a ratio of 3235:10000.
| Last Split Date | Apr 2, 2008 |
| Split Type | Reverse |
| Split Ratio | 3235:10000 |
Scores
MiMedx Group has an Altman Z-Score of 7.43 and a Piotroski F-Score of 7.
| Altman Z-Score | 7.43 |
| Piotroski F-Score | 7 |